Mailed FIT kits and reminders,
does it really help with Increased completion of colorectal cancer screening within a defined period?
research showsThe grade is C. Two large randomized trials increased screening completion by 20.5 and 20.29 percentage points. The effect is real, but completion is a health-care behavior and process endpoint intended to lead to later clinical benefit, not cancer incidence or mortality itself. The endpoint ceiling therefore gives C with 56 points.
ads claimThe supported claim is that outreach gets more people screened. Advertising a 20% reduction in colorectal cancer or mortality would extend beyond what these trials directly measured.
Useful facts when choosing a product
- FIT detects human hemoglobin in stool as a colorectal cancer screening test.
- The organized outreach bundled a letter, FIT kit, prepaid return mail, and reminders.
- No duplicate of this mailed-FIT-by-screening-completion combination was found in the existing verdict list.
Chamgap Semantic Classification Code
Candidate index · review held
P.organized-outreach-that-directly-mails-fit-kits-to-adults-overdue.diagnostic.completion-of-colorectal-cancer-screening-within-a-defined-period.increase.UNKProcedures, devices and tests > Organized outreach that directly mails FIT kits to adults overdue > Diagnostic or screening > completion of colorectal cancer screening within a defined period > Increase claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Somsouk reported 1:1 randomization, blinded providers and staff, assigned-group analysis, and counting unverified screening as incomplete, but participants were not blinded. Reuland reported an electronic allocation sequence, blinded assessors, and ITT, but participants were unblinded and the initial registry specified 12 months rather than the paper's six months. Neither trial met all four precedent-44 safeguards, giving B1. R2 remains because authors did not overlap and principal funding differed, CDC SIP versus NCI ACCSIS. Among Reuland participants with positive FIT, six-month colonoscopy completion was 14/32 (43.8%) versus 6/11 (54.5%), P=.53.
Why this is classified as C (56)
Two independent large randomized trials replicated an approximately 20-point increase in screening completion. Yet completion is a health-care behavior and process endpoint, not cancer incidence or mortality, so the ceiling is C; neither trial met all four precedent-44 safeguards, giving B1. The final grade is C with 56 points.
Counterpoint. The exact absolute gain may differ in Korea because baseline screening systems and reminder channels differ, but the core outreach effect is robust.
Rejudgment record. Cross-check applied — We cross-checked the process endpoint, allocation, analysis, masking limitations, follow-up colonoscopy, author overlap, and distinct funding streams and assigned C.
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R2 | Independently replicated across trials |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Mailed FIT kits and reminders increase colorectal cancer screening completion among overdue adults. | C | Two independent large RCTs replicated an increase of about 20 percentage points, but this is a process endpoint. |
| Mailed FIT outreach reduces colorectal cancer incidence or mortality. | ? | The pivotal trials measured screening completion, not cancer incidence or mortality directly. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Somsouk et al., J Natl Cancer Inst 2020 | Pragmatic individual randomized trial across eight primary-care clinics | 10,820 participants; 5,386 outreach and 5,434 usual care; all assigned participants analyzed | CDC U48DP004998/SIP 14-012, UCSF Academic Research Systems, NIH/NCATS UCSF-CTSI UL1 TR991872, and SF Cancer Initiative | FIT screening completion within one year | 57.9% versus 37.4%; difference 20.5 percentage points (95% CI 18.6-22.4), P<.001 | Large publicly funded replication trial |
| Reuland et al., JAMA Network Open 2024 | Pragmatic individual randomized trial across 12 clinical sites | 4,002 participants; 2,001 per group in intention-to-treat analysis | NCI ACCSIS UG3CA233251 and 5UH3CA233251, University Cancer Research Fund, and gifts from John Goodacre and Donna and Gregg Schmidt | Completion of a USPSTF-recommended colorectal cancer screening test within six months | 600/2,001 (30.0%) versus 194/2,001 (9.7%); difference 20.29 points (95% CI 17.85-22.73), P<.001; follow-up colonoscopy after positive FIT 14/32 (43.8%) versus 6/11 (54.5%), P=.53 | Independent large confirmatory trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-14).
Final verification and publication gate: Codex · Evidence date: 2026-08-14 · Corrections: none
Cite this verdict
[Chamgap] Mailed FIT kits and reminders x colorectal cancer screening completion — Evidence Grade C·56. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/mailed-fit-outreach-overdue-colorectal-cancer-screening-completion/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.